Loan & DebtJun 17, 2026, 04:06 PM
Nyxoah Receives $15M EIB Funding, Completing $110M Capital Raise
AI Summary
Nyxoah SA announced it received $15 million from the European Investment Bank (EIB), representing the second tranche of its loan facility. This non-dilutive debt funding, combined with a recent equity raise, brings the total capital raised in June 2026 to $110 million. The proceeds are primarily intended to accelerate the commercial launch of the Genio system in the United States, support research and development, and scale up manufacturing. CEO Olivier Taelman stated this financing completes a transformative period for the company, positioning it strongly for its next growth phase.
Key Highlights
- Nyxoah received $15 million from the European Investment Bank (EIB).
- This represents the second tranche of its non-dilutive loan facility.
- The funding completes a total capital raise of $110 million in June 2026.
- Proceeds will accelerate the commercial launch of the Genio system in the US.
- Funds will also support continued investment in R&D and manufacturing scale-up.
- The Genio system received FDA approval in August 2025.
Price Impact
More from NYXH